An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

August 2, 2018 updated by: GlaxoSmithKline

A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist

This study is a randomized, double-blind, double-dummy, parallel group, multicenter, non-inferiority study. The study will enroll adult and adolescent asthmatic subjects who are currently receiving mid dose inhaled corticosteroids (ICS) plus long-acting beta2-agonist (LABA) (equivalent to fluticasone propionate [FP]/salmeterol 250/50 microgram [mcg]twice daily [BD]), either via a fixed dose combination product or through separate inhalers. The study consists of a LABA washout period of 5 days and a run-in period of 4 weeks, followed by a treatment period of 24 weeks, and a follow up contact period of one week. The total duration of the study is 30 weeks. Approximately 1461 subjects will be randomized to one of the following three treatments (487 per treatment): fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg once daily (OD) in the evening (PM) via ELLIPTA™ inhaler plus placebo BD via ACCUHALER™/DISKUS™; FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler; FP 250 mcg BD via ACCUHALER/DISKUS inhaler plus placebo OD (PM) via ELLIPTA inhaler. In addition, all subjects will be supplied with albuterol/salbutamol inhalation aerosol to use as needed to treat acute asthma symptoms. This study will determine if FF/VI 100/25 mcg OD via ELLIPTA inhaler is non-inferior to FP/salmeterol 250/50 mcg BD via ACCUHALER/DISKUS inhaler in adult and adolescent asthmatic subjects already adequately controlled on a twice-daily ICS/LABA.

SERETIDE, ELLIPTA, ACCUHALER, RELVAR, and DISKUS are trademarks of the GlaxoSmithKline Group of Companies.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1526

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina, C1424BSF
        • GSK Investigational Site
      • Ciudad Autonoma de Buenos Aires, Argentina, C1425BEN
        • GSK Investigational Site
      • Ciudad Autónoma de Buenos Aires, Argentina, C1426ABP
        • GSK Investigational Site
      • Ciudad Autónoma de Buenos Aires, Argentina, C1121ABE
        • GSK Investigational Site
      • Mar del Plata, Argentina, B7600FYK
        • GSK Investigational Site
      • Mendoza, Argentina, M5500CCG
        • GSK Investigational Site
      • Mendoza, Argentina, 5500
        • GSK Investigational Site
      • San Miguel de Tucumán, Argentina, 4000
        • GSK Investigational Site
    • Buenos Aires
      • Florida, Buenos Aires, Argentina, 1602
        • GSK Investigational Site
      • La Plata, Buenos Aires, Argentina, 1900
        • GSK Investigational Site
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • GSK Investigational Site
      • Quilmes, Buenos Aires, Argentina, B1878FNR
        • GSK Investigational Site
    • Santa Fe
      • Rosario, Santa Fe, Argentina, S2000DBS
        • GSK Investigational Site
      • Rosario, Santa Fe, Argentina, S2000JKR
        • GSK Investigational Site
  • Brazil
      • São Paulo, Brazil, 04266-010
        • GSK Investigational Site
      • São Paulo, Brazil, 01323903
        • GSK Investigational Site
    • Bahía
      • Salvador, Bahía, Brazil, 41940455
        • GSK Investigational Site
    • Goiás
      • Goiânia, Goiás, Brazil, 74110 030
        • GSK Investigational Site
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000
        • GSK Investigational Site
  • Chile
      • Santiago, Chile, 7500698
        • GSK Investigational Site
      • Viña del Mar, Chile, 2520594
        • GSK Investigational Site
    • Región Del Biobio
      • Concepción, Región Del Biobio, Chile, 4070038
        • GSK Investigational Site
    • Región Metro De Santiago
      • Santiago, Región Metro De Santiago, Chile, 7510186
        • GSK Investigational Site
      • Santiago, Región Metro De Santiago, Chile, 7500692
        • GSK Investigational Site
      • Santiago, Región Metro De Santiago, Chile, 7500710
        • GSK Investigational Site
    • Valparaíso
      • Valparaiso, Valparaíso, Chile, 2341131
        • GSK Investigational Site
  • Czechia
      • Ceska Lipa, Czechia, 470 01
        • GSK Investigational Site
      • Hlucin, Czechia, 748 01
        • GSK Investigational Site
      • Hradec Kralove, Czechia, 500 02
        • GSK Investigational Site
      • Kutna Hora, Czechia, 284 01
        • GSK Investigational Site
      • Lovosice, Czechia, 410 02
        • GSK Investigational Site
      • Olomouc, Czechia, 772 00
        • GSK Investigational Site
      • Ostrava - Poruba, Czechia, 70868
        • GSK Investigational Site
      • Rokycany, Czechia, 337 01
        • GSK Investigational Site
      • Tabor, Czechia, 390 01
        • GSK Investigational Site
      • Teplice, Czechia, 415 10
        • GSK Investigational Site
      • Varnsdorf, Czechia, 407 47
        • GSK Investigational Site
  • Germany
      • Berlin, Germany, 10367
        • GSK Investigational Site
      • Berlin, Germany, 10717
        • GSK Investigational Site
      • Berlin, Germany, 10119
        • GSK Investigational Site
      • Berlin, Germany, 10787
        • GSK Investigational Site
      • Berlin, Germany, 10969
        • GSK Investigational Site
      • Berlin, Germany, 12203
        • GSK Investigational Site
      • Berlin, Germany, 13156
        • GSK Investigational Site
      • Hamburg, Germany, 22299
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Stuttgart, Baden-Wuerttemberg, Germany, 70378
        • GSK Investigational Site
    • Bayern
      • Bamberg, Bayern, Germany, 96049
        • GSK Investigational Site
      • Muenchen, Bayern, Germany, 80339
        • GSK Investigational Site
      • Muenchen, Bayern, Germany, 80539
        • GSK Investigational Site
    • Brandenburg
      • Potsdam, Brandenburg, Germany, 14469
        • GSK Investigational Site
    • Hessen
      • Frankfurt, Hessen, Germany, 60596
        • GSK Investigational Site
      • Frankfurt, Hessen, Germany, 60389
        • GSK Investigational Site
      • Marburg, Hessen, Germany, 35037
        • GSK Investigational Site
      • Neu isenburg, Hessen, Germany, 63263
        • GSK Investigational Site
    • Niedersachsen
      • Hannover, Niedersachsen, Germany, 30173
        • GSK Investigational Site
      • Peine, Niedersachsen, Germany, 31224
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Essen, Nordrhein-Westfalen, Germany, 45355
        • GSK Investigational Site
      • Essen, Nordrhein-Westfalen, Germany, 45359
        • GSK Investigational Site
      • Warendorf, Nordrhein-Westfalen, Germany, 48231
        • GSK Investigational Site
      • Witten, Nordrhein-Westfalen, Germany, 58452
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Koblenz, Rheinland-Pfalz, Germany, 56068
        • GSK Investigational Site
    • Sachsen
      • Delitzsch, Sachsen, Germany, 04509
        • GSK Investigational Site
      • Leipzg, Sachsen, Germany, 04109
        • GSK Investigational Site
      • Leipzig, Sachsen, Germany, 04275
        • GSK Investigational Site
      • Leipzig, Sachsen, Germany, 04357
        • GSK Investigational Site
      • Leipzig, Sachsen, Germany, 04207
        • GSK Investigational Site
    • Sachsen-Anhalt
      • Teuchern, Sachsen-Anhalt, Germany, 6682
        • GSK Investigational Site
    • Schleswig-Holstein
      • Geesthacht, Schleswig-Holstein, Germany, 21502
        • GSK Investigational Site
      • Luebeck, Schleswig-Holstein, Germany, 23552
        • GSK Investigational Site
      • Schleswig, Schleswig-Holstein, Germany, 24837
        • GSK Investigational Site
    • Thueringen
      • Schmoelln, Thueringen, Germany, 04626
        • GSK Investigational Site
  • Korea, Republic of
      • Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 361-763
        • GSK Investigational Site
      • Incheon, Korea, Republic of, 403-720
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 138-736
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 110-744
        • GSK Investigational Site
      • Seoul, Korea, Republic of, 135-710
        • GSK Investigational Site
      • Suwon-si, Gyeonggi-do, Korea, Republic of, 16499
        • GSK Investigational Site
  • Mexico
      • Mexico DF, Mexico, 01710
        • GSK Investigational Site
    • Jalisco
      • Zapopan, Jalisco, Mexico, 45030
        • GSK Investigational Site
      • Zapopan, Jalisco, Mexico, 45070
        • GSK Investigational Site
    • Michoacán
      • Morelia, Michoacán, Mexico, 58070
        • GSK Investigational Site
    • Nuevo León
      • Monterrey NL, Nuevo León, Mexico, 64718
        • GSK Investigational Site
    • Tabasco
      • Villahermosa, Tabasco, Mexico, 86035
        • GSK Investigational Site
  • Netherlands
      • Almelo, Netherlands, 7609 PP
        • GSK Investigational Site
      • Almere, Netherlands, 1311 RL
        • GSK Investigational Site
      • Almere, Netherlands, 1315 RC
        • GSK Investigational Site
      • Breda, Netherlands, 4819 EV
        • GSK Investigational Site
      • Breda, Netherlands, 4818 CK
        • GSK Investigational Site
      • Eindhoven, Netherlands, 5623 EJ
        • GSK Investigational Site
      • Harderwijk, Netherlands, 3844 DG
        • GSK Investigational Site
      • Hoorn, Netherlands, 1624 NP
        • GSK Investigational Site
      • Kloosterhaar, Netherlands, 7694 AC
        • GSK Investigational Site
      • Nijverdal, Netherlands, 7442 LS
        • GSK Investigational Site
      • Zutphen, Netherlands, 7207 AE
        • GSK Investigational Site
  • Romania
      • Bacau, Romania, 600252
        • GSK Investigational Site
      • Bacau, Romania, 600114
        • GSK Investigational Site
      • Brasov, Romania, 500112
        • GSK Investigational Site
      • Bucharest, Romania, 050159
        • GSK Investigational Site
      • Bucharest, Romania, 020125
        • GSK Investigational Site
      • Bucharest, Romania, 030317
        • GSK Investigational Site
      • Bucuresti, Romania, 022102
        • GSK Investigational Site
      • Cluj Napoca, Romania, 400371
        • GSK Investigational Site
      • Codlea, Romania, 505100
        • GSK Investigational Site
      • Craiova, Romania, 200345
        • GSK Investigational Site
      • Deva, Romania, 330182
        • GSK Investigational Site
      • Pitesti, Romania, 110084
        • GSK Investigational Site
      • Suceava, Romania, 720284
        • GSK Investigational Site
      • Timisoara, Romania, 300310
        • GSK Investigational Site
  • Russian Federation
      • Barnaul, Russian Federation, 656 045
        • GSK Investigational Site
      • Blagoveshchensk, Russian Federation, 675000
        • GSK Investigational Site
      • Irkutsk, Russian Federation, 664043
        • GSK Investigational Site
      • Kemerovo, Russian Federation, 650000
        • GSK Investigational Site
      • Kemerovo, Russian Federation, 650002
        • GSK Investigational Site
      • Krasnodar, Russian Federation, 350012
        • GSK Investigational Site
      • Moscow, Russian Federation, 115478
        • GSK Investigational Site
      • Moscow, Russian Federation, 123 182
        • GSK Investigational Site
      • Moscow, Russian Federation, 125315
        • GSK Investigational Site
      • Moscow, Russian Federation, 115201
        • GSK Investigational Site
      • Omsk, Russian Federation, 644112
        • GSK Investigational Site
      • Pyatigorsk, Russian Federation, 357538
        • GSK Investigational Site
      • Saint Petesburg, Russian Federation, 195030
        • GSK Investigational Site
      • Saint-Petersburg, Russian Federation, 194354
        • GSK Investigational Site
      • Saint-Petersburg, Russian Federation, 196240
        • GSK Investigational Site
      • Saratov, Russian Federation, 410028
        • GSK Investigational Site
      • St'Petersburg, Russian Federation, 197706
        • GSK Investigational Site
      • St. Petersburg, Russian Federation, 194356
        • GSK Investigational Site
      • Stavropol, Russian Federation, 355017
        • GSK Investigational Site
      • Tomsk, Russian Federation, 634009
        • GSK Investigational Site
      • Tomsk, Russian Federation, 634033
        • GSK Investigational Site
      • Ufa, Russian Federation, 450071
        • GSK Investigational Site
      • Ulyanovsk, Russian Federation, 432063
        • GSK Investigational Site
      • Vladimir, Russian Federation, 600023
        • GSK Investigational Site
      • Volgodonsk, Russian Federation, 347381
        • GSK Investigational Site
      • Voronezh, Russian Federation, 394018
        • GSK Investigational Site
  • Spain
      • Alicante, Spain, 03004
        • GSK Investigational Site
      • Alzira/Valencia, Spain, 46600
        • GSK Investigational Site
      • Badalona, Spain, 08916
        • GSK Investigational Site
      • Barcelona, Spain, 08035
        • GSK Investigational Site
      • Barcelona, Spain, 08016
        • GSK Investigational Site
      • Centelles (Barcelona), Spain, 08540
        • GSK Investigational Site
      • Madrid, Spain, 28009
        • GSK Investigational Site
      • Pozuelo De Alarcón/Madrid, Spain, 28223
        • GSK Investigational Site
      • Santander, Spain, 39008
        • GSK Investigational Site
      • Santiago de Compostela, Spain, 15706
        • GSK Investigational Site
      • Valencia, Spain, 46015
        • GSK Investigational Site
  • United States
    • California
      • Huntington Beach, California, United States, 92647
        • GSK Investigational Site
      • Riverside, California, United States, 92506
        • GSK Investigational Site
      • Rolling Hills Estates, California, United States, 90274
        • GSK Investigational Site
      • San Diego, California, United States, 92103
        • GSK Investigational Site
      • Upland, California, United States, 91786
        • GSK Investigational Site
    • Colorado
      • Denver, Colorado, United States, 80230
        • GSK Investigational Site
    • Florida
      • Miami, Florida, United States, 33165
        • GSK Investigational Site
      • Miami, Florida, United States, 33174
        • GSK Investigational Site
    • Georgia
      • Albany, Georgia, United States, 31707
        • GSK Investigational Site
    • Maryland
      • Baltimore, Maryland, United States, 21236
        • GSK Investigational Site
      • Columbia, Maryland, United States, 21044
        • GSK Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, United States, 55402
        • GSK Investigational Site
      • Plymouth, Minnesota, United States, 55441
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, United States, 65203
        • GSK Investigational Site
      • Rolla, Missouri, United States, 65401
        • GSK Investigational Site
    • Nebraska
      • Bellevue, Nebraska, United States, 68123-4303
        • GSK Investigational Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28277
        • GSK Investigational Site
      • Gastonia, North Carolina, United States, 28054
        • GSK Investigational Site
      • Hendersonville, North Carolina, United States, 28739
        • GSK Investigational Site
      • Huntersville, North Carolina, United States, 28078
        • GSK Investigational Site
    • Ohio
      • Canton, Ohio, United States, 44718
        • GSK Investigational Site
      • Cincinnati, Ohio, United States, 45231
        • GSK Investigational Site
      • Middleburg Heights, Ohio, United States, 44130
        • GSK Investigational Site
    • Oregon
      • Medford, Oregon, United States, 97504
        • GSK Investigational Site
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18020
        • GSK Investigational Site
    • South Carolina
      • Greenville, South Carolina, United States, 29615
        • GSK Investigational Site
      • Orangeburg, South Carolina, United States, 29118
        • GSK Investigational Site
      • Rock Hill, South Carolina, United States, 29732
        • GSK Investigational Site
      • Spartanburg, South Carolina, United States, 29303
        • GSK Investigational Site
    • Texas
      • Austin, Texas, United States, 78750
        • GSK Investigational Site
      • Lewisville, Texas, United States, 75067
        • GSK Investigational Site
      • Waco, Texas, United States, 76712
        • GSK Investigational Site
    • Virginia
      • Richmond, Virginia, United States, 23225
        • GSK Investigational Site
    • Wisconsin
      • Greenfield, Wisconsin, United States, 53228
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Subjects must give their signed and dated written informed consent to participate prior to commencing any study related activities.
  • Subjects must be outpatients >=12 years of age at Visit 1 who have had a diagnosis of asthma, as defined by the National Institutes of Health, for at least 12 weeks prior to Visit 1 (Note: Countries with local restrictions prohibiting enrollment of adolescents will enroll subjects >=18 years of age only).
  • Subjects may be male or an eligible female. An eligible female is defined as having non-childbearing potential or having childbearing potential and a negative urine pregnancy test at Screening and agrees to use an acceptable method of birth control consistently and correctly.
  • Subjects must have a FEV1 of >=80% of the predicted normal value.
  • Subjects are eligible if they have received mid dose ICS plus LABA (equivalent to FP/salmeterol 250/50 twice daily or an equivalent combination via separate inhalers) for at least the 12 weeks immediately preceding Visit 1.
  • All subjects must be able to replace their current SABA treatment with albuterol/salbutamol aerosol inhaler at Visit 1 for use, as needed, for the duration of the study. Subjects must be able to withhold albuterol/salbutamol for at least 6 hours prior to study visits.
  • If in the opinion of the investigator the subject's asthma is well controlled. Exclusion Criteria
  • History of Life-Threatening Asthma, defined for this protocol as an asthma episode that required intubation and/or associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 5 years.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or in the opinion of the Investigator, expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Any asthma exacerbation requiring oral corticosteroids within 12 weeks of Visit 1 or resulting in an overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  • A subject must not have current evidence of Atlectasis, Bronchopulmonary dysplasia, Chronic bronchitis, Chronic obstructive pulmonary disease, Pneumonia, Pneumothorax, Interstitial lung disease, or any evidence of concurrent respiratory disease other than asthma
  • A subject must not have any clinically significant, uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition/disease exacerbated during the study.
  • A subject must not have used any investigational drug within 30 days prior to Visit 1 or within five half-lives (t½) of the prior investigational study, whichever is longer of the two.
  • Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of RELVAR™ ELLIPTA inhaler, SERETIDE™ ACCUHALER/DISKUS inhaler or FP 250.
  • History of severe milk protein allergy.
  • Administration of prescription or non-prescription medication that would significantly affect the course of asthma, or interact with study drug.
  • A subject must not be using or require the use of immunosuppressive medications during the study.
  • A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol, including visit schedule and completion of the daily diaries.
  • Current tobacco smoker or has a smoking history of 10 pack-years (20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g., cigarettes, cigars, electronic cigarettes, or pipe tobacco).
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Fluticasone Furoate/Vilanterol 100/25 mcg
FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
Experimental: Fluticasone Propionate/Salmeterol 250/50 mcg
FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
Drug: Placebo inhalation powders via ELLIPTA inhaler
Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler
FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
Experimental: Fluticasone Propionate 250 mcg
FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
Drug: Placebo inhalation powders via ELLIPTA inhaler
Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Evening (Post Meridiem [PM]) Forced Expiratory Volume in One Second (FEV1) Using Intent-to-Treat (ITT) Population
Time Frame: Baseline and Week 24
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the mixed model repeated measures (MMRM) model and least square mean and standard error were calculated. The analysis was performed on ITT Population which comprised of all participants randomized to treatment and who received at least one dose of study medication.
Baseline and Week 24
Change From Baseline in PM FEV1 Using Per Protocol (PP) Population
Time Frame: Baseline and Week 24
FEV1 was defined as the volume of air that can be forced out in one second after taking a deep breath. FEV1 (pre-bronchodilator and pre-dose) was measured at Baseline up to Week 24 at evening using spirometry. Repeated Measures analysis was adjusted for Baseline, region, sex, age, treatment, visit, visit by Baseline interaction and visit by treatment interaction. Visit 3 values were taken as Baseline value and change from Baseline was defined as the difference between the value of the endpoint at the time point of interest and the Baseline value. Statistical analysis was performed using the MMRM models and least square mean and standard error were calculated. The analysis was performed on PP Population which comprised of all participants in the ITT Population who did not had any full protocol deviations.
Baseline and Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in the Percentage of Rescue-free 24-hour Periods
Time Frame: Baseline and Weeks 1-24
The number of inhalations of rescue medication used during the day and night were recorded by participants using an electronic diary (e-diary). A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Baseline and Weeks 1-24
Change From Baseline in the Percentage of Symptom-free 24-hour Periods
Time Frame: Baseline and Weeks 1-24
Change from Baseline in the percentage of symptom-free 24 hour period was evaluated. A 24-hour (hr) period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free. The Baseline value was derived from the last 7 days of the daily eDiary prior to the randomization of the participant. Change from Baseline was calculated as the averaged value during the 24-week treatment period minus the Baseline value.Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Baseline and Weeks 1-24
Change From Baseline in Morning (Ante Meridiem [AM]) Peak Expiratory Flow (PEF)
Time Frame: Baseline and Weeks 1-24
PEF was measured using an electric flow meter each morning. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Baseline and Weeks 1-24
Percentage of Participants With Asthma Control Test (ACT) Score Greater Than or Equal to 20
Time Frame: Week 24
The ACT was a five-item questionnaire developed as a measure of participant's asthma control. The percentage of participants controlled, defined as having ACT score greater than or equal to 20 at the end of Week 24 were analyzed using logistic regression model with covariates of Baseline ACT score, region, sex, age and treatment group.
Week 24
Change From Baseline in PM PEF
Time Frame: Baseline and Weeks 1-24
PEF was measured using an electric flow meter each evening. Change from Baseline (defined as the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily PM PEF over the 24-week treatment period minus the Baseline value. Statistical analysis was performed using an ANCOVA model with covariates of Baseline, region, sex, age and treatment and least square mean and standard error were calculated.
Baseline and Weeks 1-24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GlaxoSmithKline

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2015

Primary Completion (Actual)

November 1, 2016

Study Completion (Actual)

November 25, 2016

Study Registration Dates

First Submitted

November 24, 2014

First Submitted That Met QC Criteria

November 24, 2014

First Posted (Estimate)

November 26, 2014

Study Record Updates

Last Update Posted (Actual)

August 6, 2018

Last Update Submitted That Met QC Criteria

August 2, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 201378

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Asthma

Clinical Trials on Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe